Amgen [AMGN] vs Bristol-Myers Squibb [BMY] Detailed Stock Comparison

Amgen

NASDAQ
Loading...

Bristol-Myers Squibb

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Amgen wins in 6 metrics, Bristol-Myers Squibb wins in 13 metrics, with 0 ties. Bristol-Myers Squibb appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricAmgenBristol-Myers SquibbBetter
P/E Ratio (TTM)22.3317.73Bristol-Myers Squibb
Price-to-Book Ratio21.635.15Bristol-Myers Squibb
Debt-to-Equity Ratio756.65291.55Bristol-Myers Squibb
PEG Ratio0.24-0.77Bristol-Myers Squibb
EV/EBITDA12.946.66Bristol-Myers Squibb
Profit Margin (TTM)18.96%10.58%Amgen
Operating Margin (TTM)32.73%33.68%Bristol-Myers Squibb
EBITDA Margin (TTM)32.73%33.68%Bristol-Myers Squibb
Return on Equity99.14%29.32%Amgen
Return on Assets (TTM)7.51%8.33%Bristol-Myers Squibb
Free Cash Flow (TTM)$10.39B$13.94BBristol-Myers Squibb
Dividend Yield4.09%N/AN/A
1-Year Return-6.96%-15.25%Amgen
Price-to-Sales Ratio (TTM)4.601.88Bristol-Myers Squibb
Enterprise Value$208.88B$127.30BAmgen
EV/Revenue Ratio5.982.67Bristol-Myers Squibb
Gross Profit Margin (TTM)67.20%72.52%Bristol-Myers Squibb
Revenue per Share (TTM)$65$23Amgen
Earnings per Share (Diluted)$13.37$2.49Amgen
Beta (Stock Volatility)0.480.36Bristol-Myers Squibb
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Amgen vs Bristol-Myers Squibb Stock Performance Analysis

Loading Price Chart...

Amgen
Bristol-Myers Squibb
Amgen Stock Overview | Bristol-Myers Squibb Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen-0.37%9.67%3.65%0.19%-2.72%14.70%
Bristol-Myers Squibb-3.58%5.34%-3.54%-3.99%-23.27%-19.48%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen-6.96%29.85%25.64%98.81%427.40%286.13%
Bristol-Myers Squibb-15.25%-34.39%-26.03%-25.57%68.37%98.83%

News Based Sentiment: Amgen vs Bristol-Myers Squibb

Amgen

News based Sentiment: POSITIVE

Amgen experienced a highly positive month, driven by strong Q2 earnings that exceeded expectations, significant manufacturing investments, positive clinical trial results for Repatha leading to expanded FDA approval, and a subsequent increase in stock price. These factors collectively strengthen the investment case for Amgen.

View Amgen News Sentiment Analysis

Bristol-Myers Squibb

News based Sentiment: POSITIVE

October was a notably positive month for Bristol Myers Squibb, driven by a strong earnings report, a strategic AI partnership, and proactive measures to address drug pricing. These developments, coupled with analyst upgrades and positive insider activity, suggest a strengthening investment case and improved future prospects.

View Bristol-Myers Squibb News Sentiment Analysis

Performance & Financial Health Analysis: Amgen vs Bristol-Myers Squibb

MetricAMGNBMY
Market Information
Market Cap i$160.11B$89.86B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i3,455,19017,506,340
90 Day Avg. Volume i2,483,15312,232,973
Last Close$297.40$45.73
52 Week Range$253.30 - $335.88$42.96 - $63.33
% from 52W High-11.46%-27.79%
All-Time High$346.85 (Jul 22, 2024)$81.44 (Nov 28, 2022)
% from All-Time High-14.26%-43.85%
Growth Metrics
Quarterly Revenue Growth0.09%0.01%
Quarterly Earnings Growth0.92%-0.22%
Financial Health
Profit Margin (TTM) i0.19%0.11%
Operating Margin (TTM) i0.33%0.34%
Return on Equity (TTM) i0.99%0.29%
Debt to Equity (MRQ) i756.65291.55
Cash & Liquidity
Book Value per Share (MRQ)$13.80$8.57
Cash per Share (MRQ)$14.91$6.68
Operating Cash Flow (TTM) i$12.01B$15.90B
Levered Free Cash Flow (TTM) i$10.42B$16.19B
Dividends
Last 12-Month Dividend Yield i4.09%N/A
Last 12-Month Dividend i$11.64N/A

Valuation & Enterprise Metrics Analysis: Amgen vs Bristol-Myers Squibb

MetricAMGNBMY
Price Ratios
P/E Ratio (TTM) i22.3317.73
Forward P/E i14.446.28
PEG Ratio i0.24-0.77
Price to Sales (TTM) i4.601.88
Price to Book (MRQ) i21.635.15
Market Capitalization
Market Capitalization i$160.11B$89.86B
Enterprise Value i$208.88B$127.30B
Enterprise Value Metrics
Enterprise to Revenue i5.982.67
Enterprise to EBITDA i12.946.66
Risk & Other Metrics
Beta i0.480.36
Book Value per Share (MRQ) i$13.80$8.57

Financial Statements Comparison: Amgen vs Bristol-Myers Squibb

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)AMGNBMY
Revenue/Sales i$8.15B$12.27B
Cost of Goods Sold i$2.97B$3.37B
Gross Profit i$5.18B$8.90B
Research & Development i$1.49B$2.58B
Operating Income (EBIT) i$1.18B$3.77B
EBITDA i$4.08B$5.26B
Pre-Tax Income i$1.97B$1.77B
Income Tax i$243.00M$460.00M
Net Income (Profit) i$1.73B$1.31B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)AMGNBMY
Cash & Equivalents i$8.81B$10.88B
Total Current Assets i$26.93B$30.78B
Total Current Liabilities i$23.01B$24.07B
Long-Term Debt i$54.01B$47.51B
Total Shareholders Equity i$6.21B$17.45B
Retained Earnings i$-27.14B$16.11B
Property, Plant & Equipment iN/A$1.22B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)AMGNBMY
Operating Cash Flow i$1.71B$2.11B
Capital Expenditures i$-411.00MN/A
Free Cash Flow i$980.00M$1.69B
Debt Repayment i$-2.50BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricAMGNBMY
Shares Short i13.20M29.47M
Short Ratio i6.633.05
Short % of Float i0.02%0.01%
Average Daily Volume (10 Day) i3,455,19017,506,340
Average Daily Volume (90 Day) i2,483,15312,232,973
Shares Outstanding i537.00M2.03B
Float Shares i536.99M2.03B
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.84%0.83%

Dividend Analysis & Yield Comparison: Amgen vs Bristol-Myers Squibb

MetricAMGNBMY
Last 12-Month Dividend i$11.64N/A
Last 12-Month Dividend Yield i4.09%N/A
3-Year Avg Annual Dividend i$9.51N/A
3-Year Avg Dividend Yield i0.80%N/A
3-Year Total Dividends i$28.54N/A
Ex-Dividend DateAug 22, 2025N/A